Symbols / TBPH
TBPH Chart
About
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 984.06M |
| Enterprise Value | 680.73M | Income | 29.34M | Sales | 80.33M |
| Book/sh | 4.59 | Cash/sh | 6.51 | Dividend Yield | — |
| Payout | 0.00% | Employees | 97 | IPO | — |
| P/E | 34.07 | Forward P/E | 11.49 | PEG | — |
| P/S | 12.25 | P/B | 4.23 | P/C | — |
| EV/EBITDA | -21.84 | EV/Sales | 8.47 | Quick Ratio | 9.30 |
| Current Ratio | 9.48 | Debt/Eq | 19.17 | LT Debt/Eq | — |
| EPS (ttm) | 0.57 | EPS next Y | 1.69 | EPS Growth | — |
| Revenue Growth | 18.50% | Earnings | 2026-02-26 | ROA | -5.32% |
| ROE | 14.03% | ROIC | — | Gross Margin | 50.82% |
| Oper. Margin | -32.29% | Profit Margin | 36.53% | Shs Outstand | 50.67M |
| Shs Float | 23.30M | Short Float | 14.02% | Short Ratio | 11.35 |
| Short Interest | — | 52W High | 21.03 | 52W Low | 7.90 |
| Beta | 0.16 | Avg Volume | 459.46K | Volume | 49.61K |
| Target Price | $26.71 | Recom | Buy | Prev Close | $19.06 |
| Price | $19.42 | Change | 1.89% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$26.71
Mean price target
2. Current target
$19.42
Latest analyst target
3. DCF / Fair value
$3.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$19.42
Low
$13.00
High
$42.00
Mean
$26.71
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-03 | reit | BTIG | Buy → Buy | $40 |
| 2025-12-03 | init | Oppenheimer | — → Outperform | $27 |
| 2025-11-26 | main | BTIG | Buy → Buy | $40 |
| 2025-11-11 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-09-12 | init | B. Riley Securities | — → Buy | $28 |
| 2025-06-27 | main | BTIG | Buy → Buy | $25 |
| 2025-06-17 | init | Jones Trading | — → Buy | $24 |
| 2025-02-27 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-02-25 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-09-16 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-08-06 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-08-06 | main | TD Cowen | Hold → Hold | $9 |
| 2024-08-06 | down | Leerink Partners | Outperform → Market Perform | $10 |
| 2024-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-04-12 | init | BTIG | — → Buy | $21 |
| 2023-08-08 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-05-09 | main | HC Wainwright & Co. | — → Buy | $20 |
| 2023-02-28 | reit | HC Wainwright & Co. | — → Buy | $19 |
| 2022-11-17 | main | SVB Leerink | — → Outperform | $14 |
- CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? - Zacks Investment Research ue, 24 Feb 2026 12
- CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy? - Yahoo Finance hu, 30 Oct 2025 07
- Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy? - Nasdaq Mon, 08 Dec 2025 08
- Insider Sale: Director at $TBPH Sells 29,500 Shares | TBPH Stock News - Quiver Quantitative Fri, 14 Nov 2025 08
- Revenues Not Telling The Story For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Shares Rise 32% - simplywall.st Wed, 12 Nov 2025 08
- Theravance Biopharma Inc (NASDAQ:TBPH) Shows Strong Technical and Fundamental Momentum - ChartMill Wed, 11 Feb 2026 11
- Here's Why Shares in Theravance Biopharma Exploded Today - The Motley Fool ue, 11 Nov 2025 08
- The Technical Signals Behind (TBPH) That Institutions Follow - Stock Traders Daily Mon, 16 Feb 2026 14
- Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates - Nasdaq Mon, 10 Nov 2025 08
- $TBPH stock is up 24% today. Here's what we see in our data. - Quiver Quantitative ue, 11 Nov 2025 08
- While shareholders of Theravance Biopharma (NASDAQ:TBPH) are in the black over 1 year, those who bought a week ago aren't so fortunate - simplywall.st hu, 29 Jan 2026 08
- CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy? - Zacks Investment Research hu, 30 Oct 2025 07
- Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance Wed, 10 Dec 2025 08
- Precision Trading with Theravance Biopharma Inc. (TBPH) Risk Zones - Stock Traders Daily hu, 05 Feb 2026 12
- Is Oppenheimer’s Focus on Ampreloxetine Quietly Redefining Theravance Biopharma’s (TBPH) Risk-Reward Profile? - simplywall.st hu, 04 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 31067 | 582501 | — | Sale at price 18.75 per share. | FARNUM RHONDA | Officer | — | 2025-12-03 00:00:00 | D |
| 1 | 29501 | 590020 | — | Sale at price 20.00 per share. | BROSHY ERAN | Director | — | 2025-11-26 00:00:00 | D |
| 2 | 9900 | — | — | Stock Gift at price 0.00 per share. | WINNINGHAM RICK E | Chief Executive Officer | — | 2025-11-19 00:00:00 | D |
| 3 | 59000 | 1068250 | — | Sale at price 17.00 - 18.50 per share. | BROSHY ERAN | Director | — | 2025-11-11 00:00:00 | D |
| 4 | 45000 | 809250 | — | Sale at price 17.00 - 18.50 per share. | BROSHY ERAN | Director | — | 2025-11-11 00:00:00 | D |
| 5 | 14000 | 142100 | — | Conversion of Exercise of derivative security at price 10.15 per share. | BROSHY ERAN | Director | — | 2025-11-11 00:00:00 | D |
| 6 | 10000 | 113870 | — | Sale at price 11.39 per share. | FARNUM RHONDA | Officer | — | 2025-07-14 00:00:00 | D |
| 7 | 20000 | — | — | Stock Gift at price 0.00 per share. | WINNINGHAM RICK E | Chief Executive Officer | — | 2025-06-23 00:00:00 | D |
| 8 | 9600 | — | — | Stock Gift at price 0.00 per share. | WINNINGHAM RICK E | Chief Executive Officer | — | 2025-06-13 00:00:00 | D |
| 9 | 24000 | 264000 | — | Sale at price 11.00 per share. | FARNUM RHONDA | Officer | — | 2025-06-02 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -947.73K | -576.03K | -3.33M | -12.09K |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.00 |
| NormalizedEBITDA | -33.94M | -39.92M | -63.55M | -227.94M |
| TotalUnusualItems | -4.51M | -2.74M | -15.87M | -20.14M |
| TotalUnusualItemsExcludingGoodwill | -4.51M | -2.74M | -15.87M | -20.14M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -56.42M | -55.19M | -92.82M | -265.07M |
| ReconciledDepreciation | 3.62M | 4.26M | 7.02M | 8.60M |
| EBITDA | -38.45M | -42.66M | -79.42M | -248.08M |
| EBIT | -42.07M | -46.92M | -86.45M | -256.68M |
| NetInterestIncome | 2.33M | 6.77M | 2.18M | -7.44M |
| InterestExpense | 2.55M | 2.35M | 6.37M | 8.55M |
| InterestIncome | 4.88M | 9.12M | 8.54M | 1.11M |
| NormalizedIncome | -52.85M | -53.03M | -80.29M | -244.94M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -56.42M | -55.19M | 872.13M | -199.43M |
| TotalExpenses | 106.82M | 110.72M | 130.47M | 292.95M |
| TotalOperatingIncomeAsReported | -46.95M | -56.03M | -91.96M | -257.78M |
| DilutedAverageShares | 48.85M | 55.30M | 73.59M | 69.46M |
| BasicAverageShares | 48.85M | 55.30M | 73.59M | 69.46M |
| DilutedEPS | -1.15 | -1.00 | 11.85 | -2.87 |
| BasicEPS | -1.15 | -1.00 | 11.85 | -2.87 |
| DilutedNIAvailtoComStockholders | -56.42M | -55.19M | 872.13M | -199.43M |
| NetIncomeCommonStockholders | -56.42M | -55.19M | 872.13M | -199.43M |
| NetIncome | -56.42M | -55.19M | 872.13M | -199.43M |
| NetIncomeIncludingNoncontrollingInterests | -56.42M | -55.19M | 872.13M | -199.43M |
| NetIncomeDiscontinuousOperations | 0.00 | 964.96M | 65.64M | |
| NetIncomeContinuousOperations | -56.42M | -55.19M | -92.82M | -265.07M |
| TaxProvision | 11.80M | 5.92M | 9.00K | -151.00K |
| PretaxIncome | -44.61M | -49.27M | -92.81M | -265.22M |
| OtherIncomeExpense | -4.51M | -2.74M | -15.87M | -20.14M |
| SpecialIncomeCharges | -4.51M | -2.74M | -15.87M | -20.14M |
| OtherSpecialCharges | 3.03M | |||
| ImpairmentOfCapitalAssets | 4.51M | 0.00 | ||
| RestructuringAndMergernAcquisition | 0.00 | 2.74M | 12.84M | 20.14M |
| EarningsFromEquityInterest | 103.99M | |||
| NetNonOperatingInterestIncomeExpense | 2.33M | 6.77M | 2.18M | -7.44M |
| InterestExpenseNonOperating | 2.55M | 2.35M | 6.37M | 8.55M |
| InterestIncomeNonOperating | 4.88M | 9.12M | 8.54M | 1.11M |
| OperatingIncome | -42.44M | -53.29M | -79.12M | -237.64M |
| OperatingExpense | 106.82M | 110.72M | 130.47M | 292.95M |
| ResearchAndDevelopment | 37.64M | 40.62M | 63.39M | 193.66M |
| SellingGeneralAndAdministration | 69.17M | 70.09M | 67.07M | 99.30M |
| TotalRevenue | 64.38M | 57.42M | 51.35M | 55.31M |
| OperatingRevenue | 64.38M | 57.42M | 51.35M | 55.31M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 49.47M | 48.09M | 65.23M | 74.44M |
| ShareIssued | 49.47M | 48.09M | 65.23M | 74.44M |
| NetDebt | 526.38M | |||
| TotalDebt | 49.82M | 49.16M | 52.16M | 669.52M |
| TangibleBookValue | 175.54M | 213.00M | 441.80M | -338.57M |
| InvestedCapital | 175.54M | 213.00M | 441.80M | 277.76M |
| WorkingCapital | 128.98M | 108.77M | 324.75M | 191.28M |
| NetTangibleAssets | 175.54M | 213.00M | 441.80M | -338.57M |
| CapitalLeaseObligations | 49.82M | 49.16M | 52.16M | 53.18M |
| CommonStockEquity | 175.54M | 213.00M | 441.80M | -338.57M |
| TotalCapitalization | 175.54M | 213.00M | 441.80M | 260.82M |
| TotalEquityGrossMinorityInterest | 175.54M | 213.00M | 441.80M | -338.57M |
| StockholdersEquity | 175.54M | 213.00M | 441.80M | -338.57M |
| GainsLossesNotAffectingRetainedEarnings | 7.00K | -65.00K | -15.00K | 0.00 |
| OtherEquityAdjustments | 7.00K | -65.00K | -15.00K | |
| RetainedEarnings | -965.52M | -909.10M | -853.91M | -1.73B |
| AdditionalPaidInCapital | 1.14B | 1.12B | 1.30B | 1.39B |
| CapitalStock | 0.00 | 0.00 | 1.00K | 1.00K |
| CommonStock | 0.00 | 0.00 | 1.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 178.62M | 169.00M | 165.60M | 713.39M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 146.53M | 144.24M | 136.88M | 654.80M |
| OtherNonCurrentLiabilities | 32.22M | 33.71M | 27.09M | 2.18M |
| TradeandOtherPayablesNonCurrent | 75.20M | 65.29M | 64.19M | 240.00K |
| NonCurrentDeferredLiabilities | 0.00 | 192.00K | 310.00K | |
| NonCurrentDeferredRevenue | 0.00 | 192.00K | 310.00K | |
| LongTermDebtAndCapitalLeaseObligation | 39.11M | 45.24M | 45.41M | 652.08M |
| LongTermCapitalLeaseObligation | 39.11M | 45.24M | 45.41M | 52.68M |
| LongTermDebt | 599.39M | |||
| CurrentLiabilities | 32.09M | 24.77M | 28.71M | 58.59M |
| CurrentDeferredLiabilities | 24.00K | 98.00K | ||
| CurrentDeferredRevenue | 24.00K | 98.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 10.71M | 3.92M | 6.75M | 17.44M |
| CurrentCapitalLeaseObligation | 10.71M | 3.92M | 6.75M | 503.00K |
| CurrentDebt | 16.94M | |||
| OtherCurrentBorrowings | 16.94M | |||
| PayablesAndAccruedExpenses | 21.37M | 20.84M | 21.96M | 41.05M |
| CurrentAccruedExpenses | 13.28M | 12.83M | 20.41M | 37.95M |
| InterestPayable | 0.00 | 3.94M | ||
| Payables | 8.10M | 8.01M | 1.55M | 3.10M |
| OtherPayable | 6.49M | |||
| TotalTaxPayable | 5.85M | 0.00 | ||
| IncomeTaxPayable | 5.85M | 0.00 | ||
| AccountsPayable | 2.24M | 1.52M | 1.55M | 3.10M |
| TotalAssets | 354.16M | 382.00M | 607.40M | 374.82M |
| TotalNonCurrentAssets | 193.09M | 248.46M | 253.94M | 124.95M |
| OtherNonCurrentAssets | 157.32M | 203.10M | 201.94M | 4.07M |
| InvestmentsAndAdvances | 0.00 | 67.54M | ||
| LongTermEquityInvestment | 0.00 | 67.54M | ||
| NetPPE | 35.77M | 45.35M | 52.00M | 53.35M |
| AccumulatedDepreciation | -22.40M | -21.58M | -32.84M | -38.49M |
| GrossPPE | 58.17M | 66.94M | 84.84M | 91.84M |
| Leases | 25.32M | 26.21M | 24.58M | 24.05M |
| OtherProperties | 28.39M | 36.35M | 55.57M | 59.78M |
| MachineryFurnitureEquipment | 4.46M | 4.38M | 4.68M | 8.01M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 161.07M | 133.54M | 353.46M | 249.87M |
| OtherCurrentAssets | 4.20M | 11.60M | 7.68M | 8.56M |
| PrepaidAssets | 73.00K | 2.04M | 1.51M | 10.24M |
| Receivables | 68.44M | 17.47M | 16.79M | 57.60M |
| OtherReceivables | 50.00M | |||
| DuefromRelatedPartiesCurrent | 0.00 | 43.53M | ||
| AccountsReceivable | 18.44M | 17.47M | 16.79M | 14.06M |
| CashCashEquivalentsAndShortTermInvestments | 88.35M | 102.43M | 327.48M | 173.47M |
| OtherShortTermInvestments | 50.55M | 62.88M | 29.31M | 83.51M |
| CashAndCashEquivalents | 37.80M | 39.55M | 298.17M | 89.96M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -11.87M | -29.48M | -187.56M | -211.26M |
| RepurchaseOfCapitalStock | -3.10M | -199.55M | -132.28M | -9.06M |
| RepaymentOfDebt | 0.00 | -631.60M | -10.73M | |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 99.00K | 0.00 | 0.00 | 108.18M |
| CapitalExpenditure | -332.00K | -2.49M | -572.00K | -3.41M |
| InterestPaidSupplementalData | 0.00 | 22.24M | 39.03M | |
| IncomeTaxPaidSupplementalData | 109.00K | 24.00K | 117.97M | |
| EndCashPosition | 38.63M | 40.38M | 299.01M | 90.80M |
| BeginningCashPosition | 40.38M | 299.01M | 90.80M | 82.30M |
| ChangesInCash | -1.75M | -258.63M | 208.21M | 8.50M |
| FinancingCashFlow | -2.50M | -198.93M | -758.81M | 91.86M |
| CashFromDiscontinuedFinancingActivities | 0.00 | -20.19M | 0.00 | |
| CashFlowFromContinuingFinancingActivities | -2.50M | -198.93M | -738.62M | 91.86M |
| NetOtherFinancingCharges | 24.46M | |||
| ProceedsFromStockOptionExercised | 508.00K | 618.00K | 802.00K | 3.47M |
| NetCommonStockIssuance | -3.00M | -199.55M | -132.28M | 99.12M |
| CommonStockPayments | -3.10M | -199.55M | -132.28M | -9.06M |
| CommonStockIssuance | 99.00K | 0.00 | 0.00 | 108.18M |
| NetIssuancePaymentsOfDebt | 0.00 | -631.60M | -10.73M | |
| NetLongTermDebtIssuance | 0.00 | -631.60M | -10.73M | |
| LongTermDebtPayments | 0.00 | -631.60M | -10.73M | |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | 12.28M | -32.70M | 1.15B | 124.49M |
| CashFromDiscontinuedInvestingActivities | 0.00 | 1.10B | 0.00 | |
| CashFlowFromContinuingInvestingActivities | 12.28M | -32.70M | 58.88M | 124.49M |
| NetOtherInvestingChanges | 2.71M | |||
| NetInvestmentPurchaseAndSale | 12.62M | -31.72M | 54.87M | 127.89M |
| SaleOfInvestment | 155.65M | 102.81M | 158.02M | 286.20M |
| PurchaseOfInvestment | -143.03M | -134.53M | -103.14M | -158.31M |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | -332.00K | -975.00K | 1.29M | -3.40M |
| SaleOfPPE | 0.00 | 1.51M | 1.87M | 6.00K |
| PurchaseOfPPE | -332.00K | -2.49M | -572.00K | -3.41M |
| OperatingCashFlow | -11.54M | -27.00M | -186.99M | -207.86M |
| CashFromDiscontinuedOperatingActivities | 0.00 | -184.57M | 27.92M | |
| CashFlowFromContinuingOperatingActivities | -11.54M | -27.00M | -2.42M | -235.78M |
| ChangeInWorkingCapital | 20.36M | -8.34M | 42.35M | -39.55M |
| ChangeInOtherWorkingCapital | 9.91M | 886.00K | 63.76M | -11.65M |
| ChangeInOtherCurrentLiabilities | 129.00K | 4.55M | -1.55M | -965.00K |
| ChangeInOtherCurrentAssets | -296.00K | -1.55M | -8.23M | -972.00K |
| ChangeInPayablesAndAccruedExpense | 2.22M | -7.09M | -16.94M | -40.76M |
| ChangeInAccruedExpense | 1.47M | -7.09M | -15.33M | -37.23M |
| ChangeInInterestPayable | 0.00 | -1.25M | 0.00 | |
| ChangeInPayable | 750.00K | 6.00K | -1.61M | -3.53M |
| ChangeInAccountPayable | 750.00K | 6.00K | -1.61M | -3.53M |
| ChangeInPrepaidAssets | 9.36M | -4.45M | 8.03M | 13.00M |
| ChangeInReceivables | -966.00K | -689.00K | -2.72M | 1.80M |
| ChangesInAccountReceivables | -966.00K | -689.00K | -2.72M | 1.80M |
| OtherNonCashItems | 2.55M | 2.35M | 974.00K | -1.85M |
| StockBasedCompensation | 21.39M | 25.37M | 39.73M | 62.06M |
| AssetImpairmentCharge | 4.51M | 0.00 | ||
| DeferredTax | -7.57M | 3.21M | 0.00 | |
| DeferredIncomeTax | -7.57M | 3.21M | 0.00 | |
| DepreciationAmortizationDepletion | 3.62M | 4.26M | 7.02M | 8.60M |
| DepreciationAndAmortization | 3.62M | 4.26M | 7.02M | 8.60M |
| AmortizationCashFlow | -2.51M | -1.90M | -681.00K | 10.00K |
| AmortizationOfIntangibles | -2.51M | -1.90M | -681.00K | 10.00K |
| Depreciation | 6.12M | 6.15M | 7.71M | 8.59M |
| OperatingGainsLosses | 34.00K | 1.35M | 317.00K | 39.00K |
| EarningsLossesFromEquityInvestments | -44.52M | |||
| GainLossOnSaleOfPPE | 34.00K | 1.35M | -8.00K | 39.00K |
| NetIncomeFromContinuingOperations | -56.42M | -55.19M | -92.82M | -265.07M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TBPH
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|